Use of oral anticoagulants after ischaemic stroke in patients with atrial fibrillation and cancer.

OAC treatment in poststroke patients with AF and active cancer has increased after the introduction of NOACs. However, the growing treatment gap in these patients compared to that in noncancer patients raises the possibility of underutilization.